TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing

Stock News

Sep 04

TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) have recently completed first patient dosing.

This trial is an open-label, multi-center Phase II clinical study conducted in China to evaluate the efficacy and safety of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) combined with Tinengotinib tablets for treating advanced hepatocellular carcinoma. The primary objective of the trial is to assess the safety and efficacy of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) respectively combined with Tinengotinib tablets or Tinengotinib monotherapy for advanced hepatocellular carcinoma treatment.

The trial's target population includes patients with advanced hepatocellular carcinoma who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment. TRANSTHERA has entered into a cooperation agreement with AKESO, with both parties jointly conducting clinical combination drug development in the field of hepatocellular carcinoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1153459765"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153459765\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153459765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153459765","market":"nz","top_or_hot":-1,"title":"TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) have recently completed first patient dosing.</p>\n<p>This trial is an open-label, multi-center Phase II clinical study conducted in China to evaluate the efficacy and safety of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) combined with Tinengotinib tablets for treating advanced hepatocellular carcinoma. The primary objective of the trial is to assess the safety and efficacy of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) respectively combined with Tinengotinib tablets or Tinengotinib monotherapy for advanced hepatocellular carcinoma treatment.</p>\n<p>The trial's target population includes patients with advanced hepatocellular carcinoma who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment. TRANSTHERA has entered into a cooperation agreement with AKESO, with both parties jointly conducting clinical combination drug development in the field of hepatocellular carcinoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-04 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) have recently completed first patient dosing.</p>\n<p>This trial is an open-label, multi-center Phase II clinical study conducted in China to evaluate the efficacy and safety of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) combined with Tinengotinib tablets for treating advanced hepatocellular carcinoma. The primary objective of the trial is to assess the safety and efficacy of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) respectively combined with Tinengotinib tablets or Tinengotinib monotherapy for advanced hepatocellular carcinoma treatment.</p>\n<p>The trial's target population includes patients with advanced hepatocellular carcinoma who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment. TRANSTHERA has entered into a cooperation agreement with AKESO, with both parties jointly conducting clinical combination drug development in the field of hepatocellular carcinoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0540923850.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1153459765","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153459765","pubTimestamp":1756997181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","BK1161":"生物科技","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK4023":"应用软件","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","09926":"康方生物","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","PD":"PagerDuty, Inc.","BK1574":"生物医药B类股","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","02617":"药捷安康-B","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC"},"translate_title":"Tranthera-B（02617）：Tinengotinib联合康方康坦尼的II期临床试验®（卡多尼单抗，PD-1/CTLA-4）/Ivonesca®（Ivonescimab，PD-1/VEGF）完成首次患者给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"09926":1,"PD":1},"content_text":"TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) have recently completed first patient dosing.\nThis trial is an open-label, multi-center Phase II clinical study conducted in China to evaluate the efficacy and safety of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) combined with Tinengotinib tablets for treating advanced hepatocellular carcinoma. The primary objective of the trial is to assess the safety and efficacy of Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) respectively combined with Tinengotinib tablets or Tinengotinib monotherapy for advanced hepatocellular carcinoma treatment.\nThe trial's target population includes patients with advanced hepatocellular carcinoma who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment. TRANSTHERA has entered into a cooperation agreement with AKESO, with both parties jointly conducting clinical combination drug development in the field of hepatocellular carcinoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}